Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.

Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.

PLoS One. 2019 Jul 24;14(7):e0220142. doi: 10.1371/journal.pone.0220142. eCollection 2019.

2.

Decision Aids for Prostate Cancer Screening Choice: A Systematic Review and Meta-analysis.

Riikonen JM, Guyatt GH, Kilpeläinen TP, Craigie S, Agarwal A, Agoritsas T, Couban R, Dahm P, Järvinen P, Montori V, Power N, Richard PO, Rutanen J, Santti H, Tailly T, Violette PD, Zhou Q, Tikkinen KAO.

JAMA Intern Med. 2019 Jun 24. doi: 10.1001/jamainternmed.2019.0763. [Epub ahead of print]

3.

Public, health professional and legislator perspectives on the concept of psychiatric disease: a population-based survey.

Tikkinen KAO, Rutanen J, Frances A, Perry BL, Dennis BB, Agarwal A, Maqbool A, Ebrahim S, Leinonen JS, Järvinen TLN, Guyatt GH.

BMJ Open. 2019 Jun 4;9(6):e024265. doi: 10.1136/bmjopen-2018-024265.

4.

Incidence of inflammatory joint diseases in Finland: results from a population-based epidemiological study.

Kononoff A, Arstila L, Pussinen P, Kautiainen H, Elfving P, Savolainen E, Niinisalo H, Rutanen J, Marjoniemi O, Kaipiainen-Seppänen O.

Rheumatol Int. 2017 Oct;37(10):1693-1700. doi: 10.1007/s00296-017-3779-1. Epub 2017 Aug 8.

PMID:
28791449
5.

Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010.

Elfving P, Marjoniemi O, Niinisalo H, Kononoff A, Arstila L, Savolainen E, Rutanen J, Kaipiainen-Seppänen O.

Rheumatol Int. 2016 Jul;36(7):917-24. doi: 10.1007/s00296-016-3474-7. Epub 2016 Apr 6.

PMID:
27053177
6.

Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.

Rutanen J, Kononoff A, Arstila L, Elfving P, Koskela H, Kaipiainen-Seppänen O.

Scand J Rheumatol. 2014;43(3):254-6. doi: 10.3109/03009742.2013.868511. Epub 2014 Mar 21. No abstract available.

PMID:
24650220
7.

Regional variation and outcome of out-of-hospital cardiac arrest (ohca) in Finland - the Finnresusci study.

Hiltunen P, Kuisma M, Silfvast T, Rutanen J, Vaahersalo J, Kurola J; Finnresusci Prehospital Study Group.

Scand J Trauma Resusc Emerg Med. 2012 Dec 17;20:80. doi: 10.1186/1757-7241-20-80.

8.

Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial.

Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, Klemenzson G, Pott F, Bødker KD, Bådstøløkken PM, Bendtsen A, Søe-Jensen P, Tousi H, Bestle M, Pawlowicz M, Winding R, Bülow HH, Kancir C, Steensen M, Nielsen J, Fogh B, Madsen KR, Larsen NH, Carlsson M, Wiis J, Petersen JA, Iversen S, Schøidt O, Leivdal S, Berezowicz P, Pettilä V, Ruokonen E, Klepstad P, Karlsson S, Kaukonen M, Rutanen J, Karason S, Kjældgaard AL, Holst LB, Wernerman J; Scandinavian Critical Care Trials Group.

Trials. 2011 Jan 27;12:24. doi: 10.1186/1745-6215-12-24.

9.

Effect of levosimendan in experimental verapamil-induced myocardial depression.

Kurola J, Leppikangas H, Magga J, Lindgren L, Kiviniemi V, Rutanen J, Ruokonen E.

Scand J Trauma Resusc Emerg Med. 2010 Mar 11;18:12. doi: 10.1186/1757-7241-18-12.

10.

SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity.

Rutanen J, Yaluri N, Modi S, Pihlajamäki J, Vänttinen M, Itkonen P, Kainulainen S, Yamamoto H, Lagouge M, Sinclair DA, Elliott P, Westphal C, Auwerx J, Laakso M.

Diabetes. 2010 Apr;59(4):829-35. doi: 10.2337/db09-1191. Epub 2010 Jan 27.

11.

Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients--EUGENE2 study.

Boesgaard TW, Gjesing AP, Grarup N, Rutanen J, Jansson PA, Hribal ML, Sesti G, Fritsche A, Stefan N, Staiger H, Häring H, Smith U, Laakso M, Pedersen O, Hansen T; EUGENE2 Consortium.

PLoS One. 2009 Sep 30;4(9):e7236. doi: 10.1371/journal.pone.0007236.

12.

Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study.

Leppikangas H, Ruokonen E, Rutanen J, Kiviniemi V, Lindgren L, Kurola J.

Ann Emerg Med. 2009 Dec;54(6):811-817.e1-3. doi: 10.1016/j.annemergmed.2009.06.512. Epub 2009 Sep 19.

PMID:
19766354
13.

PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries.

Karvinen H, Rutanen J, Leppänen O, Lach R, Levonen AL, Eriksson U, Ylä-Herttuala S.

Eur J Clin Invest. 2009 Apr;39(4):320-7. doi: 10.1111/j.1365-2362.2009.02095.x.

PMID:
19292888
14.

Single nucleotide polymorphisms of the MCHR1 gene do not affect metabolism in humans.

Rutanen J, Pihlajamäki J, Vänttinen M, Salmenniemi U, Ruotsalainen E, Kuulasmaa T, Kainulainen S, Kuusisto J, Laakso M.

Obesity (Silver Spring). 2007 Dec;15(12):2902-7. doi: 10.1038/oby.2007.345.

15.

Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta.

Bräsen JH, Leppänen O, Inkala M, Heikura T, Levin M, Ahrens F, Rutanen J, Pietsch H, Bergqvist D, Levonen AL, Basu S, Zeller T, Klöppel G, Laukkanen MO, Ylä-Herttuala S.

J Am Coll Cardiol. 2007 Dec 4;50(23):2249-53. Epub 2007 Nov 19.

16.

Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo.

Levonen AL, Inkala M, Heikura T, Jauhiainen S, Jyrkkänen HK, Kansanen E, Määttä K, Romppanen E, Turunen P, Rutanen J, Ylä-Herttuala S.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):741-7. Epub 2007 Jan 25.

PMID:
17255530
17.

Single nucleotide polymorphisms of the melanocortin-3 receptor gene are associated with substrate oxidation and first-phase insulin secretion in offspring of type 2 diabetic subjects.

Rutanen J, Pihlajamäki J, Vänttinen M, Salmenniemi U, Ruotsalainen E, Kuulasmaa T, Kainulainen S, Laakso M.

J Clin Endocrinol Metab. 2007 Mar;92(3):1112-7. Epub 2006 Dec 27. Erratum in: J Clin Endocrinol Metab. 2008 Apr;93(4):1506.

PMID:
17192297
18.

Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia.

Pätilä T, Ikonen T, Rutanen J, Ahonen A, Lommi J, Lappalainen K, Krogerus L, Ihlberg L, Partanen TA, Lähteenoja L, Virtanen K, Alitalo K, Ylä-Herttuala S, Harjula A.

J Heart Lung Transplant. 2006 Feb;25(2):206-13. Epub 2005 Dec 9.

PMID:
16446222
19.

Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model.

Puhakka HL, Turunen P, Rutanen J, Hiltunen MO, Turunen MP, Yla-Herttuala S.

J Vasc Res. 2005 Sep-Oct;42(5):361-7. Epub 2005 Jul 19.

PMID:
16037681
20.

Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism.

Rutanen J, Turunen AM, Teittinen M, Rissanen TT, Heikura T, Koponen JK, Gruchala M, Inkala M, Jauhiainen S, Hiltunen MO, Turunen MP, Stacker SA, Achen MG, Ylä-Herttuala S.

Gene Ther. 2005 Jun;12(12):980-7.

PMID:
15759018
21.

Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta.

Turunen P, Puhakka H, Rutanen J, Hiltunen MO, Heikura T, Gruchala M, Ylä-Herttuala S.

Atherosclerosis. 2005 Mar;179(1):27-33. Epub 2004 Dec 13.

PMID:
15721006
22.

Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia.

Rissanen TT, Rutanen J, Ylä-Herttuala S.

Adv Genet. 2004;52:117-64. Review.

PMID:
15522734
23.

The Val103Ile polymorphism of melanocortin-4 receptor regulates energy expenditure and weight gain.

Rutanen J, Pihlajamäki J, Karhapää P, Vauhkonen I, Kuusisto J, Moilanen Mykkänen L, Laakso M.

Obes Res. 2004 Jul;12(7):1060-6.

24.

HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array.

Tuomisto TT, Rissanen TT, Vajanto I, Korkeela A, Rutanen J, Ylä-Herttuala S.

Atherosclerosis. 2004 May;174(1):111-20.

PMID:
15135259
25.

Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors.

Gruchała M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I, Kholová I, Markkanen JE, Rutanen J, Heikura T, Alitalo K, Büeler H, Ylä-Herttuala S.

J Gene Med. 2004 May;6(5):545-54.

PMID:
15133765
26.

Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.

Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivelä A, Hedman A, Hedman M, Heikura T, Ordén MR, Stacker SA, Achen MG, Hartikainen J, Ylä-Herttuala S.

Circulation. 2004 Mar 2;109(8):1029-35. Epub 2004 Feb 16.

PMID:
14967735
27.

Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits.

Leppänen O, Rutanen J, Hiltunen MO, Rissanen TT, Turunen MP, Sjöblom T, Brüggen J, Bäckström G, Carlsson M, Buchdunger E, Bergqvist D, Alitalo K, Heldin CH, Ostman A, Ylä-Herttuala S.

Circulation. 2004 Mar 9;109(9):1140-6. Epub 2004 Feb 9.

PMID:
14769706
28.

Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors.

Tuomisto TT, Korkeela A, Rutanen J, Viita H, Bräsen JH, Riekkinen MS, Rissanen TT, Karkola K, Kiraly Z, Kölble K, Ylä-Herttuala S.

Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2235-40. Epub 2003 Oct 23.

PMID:
14576072
29.

Vascular endothelial growth factor-D expression in human atherosclerotic lesions.

Rutanen J, Leppänen P, Tuomisto TT, Rissanen TT, Hiltunen MO, Vajanto I, Niemi M, Häkkinen T, Karkola K, Stacker SA, Achen MG, Alitalo K, Ylä-Herttuala S.

Cardiovasc Res. 2003 Oct 1;59(4):971-9.

PMID:
14553837
30.

Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo.

Hiltunen MO, Ruuskanen M, Huuskonen J, Mähönen AJ, Ahonen M, Rutanen J, Kosma VM, Mahonen A, Kröger H, Ylä-Herttuala S.

FASEB J. 2003 Jun;17(9):1147-9. Epub 2003 Apr 8.

PMID:
12692089
31.

Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model.

Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I, Jauhiainen S, Cashion L, Gruchala M, Närvänen O, Taipale P, Kauppinen RA, Rubanyi GM, Ylä-Herttuala S.

FASEB J. 2003 Jan;17(1):100-2. Epub 2002 Nov 15.

PMID:
12475908
32.

Post-intervention vessel remodeling.

Rutanen J, Puhakka H, Ylä-Herttuala S.

Gene Ther. 2002 Nov;9(22):1487-91. Review.

33.

Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta.

Laukkanen MO, Kivelä A, Rissanen T, Rutanen J, Karkkainen MK, Leppanen O, Bräsen JH, Yla-Herttuala S.

Circulation. 2002 Oct 8;106(15):1999-2003.

PMID:
12370226
34.

Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer.

Turunen MP, Puhakka HL, Koponen JK, Hiltunen MO, Rutanen J, Leppänen O, Turunen AM, Närvänen A, Newby AC, Baker AH, Ylä-Herttuala S.

Mol Ther. 2002 Sep;6(3):306-12.

35.

Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ.

Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Närvänen O, Manninen H, Räsänen H, Hippeläinen M, Alhava E, Ylä-Herttuala S.

J Gene Med. 2002 Jul-Aug;4(4):371-80.

PMID:
12124979
36.

Gene therapy for restenosis: current status.

Rutanen J, Markkanen J, Ylä-Herttuala S.

Drugs. 2002;62(11):1575-85. Review.

PMID:
12109921
37.

DNA hypomethylation and methyltransferase expression in atherosclerotic lesions.

Hiltunen MO, Turunen MP, Häkkinen TP, Rutanen J, Hedman M, Mäkinen K, Turunen AM, Aalto-Setälä K, Ylä-Herttuala S.

Vasc Med. 2002 Feb;7(1):5-11.

PMID:
12083735
38.

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration.

Rissanen TT, Vajanto I, Hiltunen MO, Rutanen J, Kettunen MI, Niemi M, Leppänen P, Turunen MP, Markkanen JE, Arve K, Alhava E, Kauppinen RA, Ylä-Herttuala S.

Am J Pathol. 2002 Apr;160(4):1393-403.

39.

Clinical applications of vascular gene therapy.

Rutanen J, Rissanen TT, Kivelä A, Vajanto I, Ylä-Herttuala S.

Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review.

PMID:
11139796

Supplemental Content

Loading ...
Support Center